Pharmaceutical

Kronos mulls ‘strategic alternatives’ after axing cancer drug development

The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable risk-benefit profile”.

Nov 15, 2024 - 06:00
Kronos mulls ‘strategic alternatives’ after axing cancer drug development
The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable risk-benefit profile”.
Read the original article

Tags:

Previous Article

Leading account and intent-based sales and marketing providers and technology so...

Next Article

Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints 

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Beta Bionics’ automated insulin delivery system picks up manufacturing partner

Beta Bionics’ automated insulin delivery system picks u...

May 26, 2023

STAT+: ADA says all diabetes patients should be screened for nonalcoholic fatty liver disease

STAT+: ADA says all diabetes patients should be screene...

Jun 26, 2023

STAT+: Rune Labs, which makes an app to track Parkinson’s symptoms, raises $12 million

STAT+: Rune Labs, which makes an app to track Parkinson...

Jan 12, 2024